Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685346 | 0.88 | MAPT (0.35) | F2F10MAPTALDH1A1MEN1 | |
| SCHEMBL2473536 | 0.82 | F2 (0.48) | F2F10MAPTALDH1A1MEN1 | |
| SCHEMBL3680306 | 0.81 | ALDH1A1 (0.40) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL2475744 | 0.80 | SMYD2 (0.34) | F2F10MAPTALDH1A1MEN1 | |
| SCHEMBL3423017 | 0.78 | MAPT (0.33) | F2MAPTALDH1A1MEN1THRB | |
| SCHEMBL3686796 | 0.78 | NR4A1 (0.44) | MAPTALDH1A1MEN1THRBKMT2A | |
| SCHEMBL3676961 | 0.75 | NR4A1 (0.43) | MAPTALDH1A1KDM4ELMNAGAA | |
| SCHEMBL9913271 | 0.74 | F2 (0.39) | F2F10MAPTALDH1A1KDM4E | |
| SCHEMBL3643360 | 0.74 | F2 (0.37) | F2F10MAPTALDH1A1MEN1 | |
| SCHEMBL3675640 | 0.74 | ALDH1A1 (0.41) | MAPTALDH1A1MEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| EP-2167499-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, OXA1L, PPOX | F2 46/4885F10 395/4885MAPT 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.